Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?

Core Insights - ChromaDex (CDXC) has significantly outperformed the Medical sector with a year-to-date return of approximately 164.3%, compared to the sector's average gain of 8.9% [4] - The Zacks Rank for ChromaDex is 1 (Strong Buy), indicating a favorable outlook based on earnings estimate revisions [3] - The consensus estimate for ChromaDex's full-year earnings has increased by 142.9% over the past 90 days, reflecting strong analyst sentiment [4] Company Performance - ChromaDex is part of the Medical - Biomedical and Genetics industry, which consists of 495 companies and currently ranks 84 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has experienced an average loss of 1.9% this year, highlighting ChromaDex's superior performance within its industry [6] Comparison with Peers - Clover Health Investments, Corp. (CLOV) has also outperformed the Medical sector with a return of 203.5% year-to-date [5] - Clover Health's consensus EPS estimate has risen by 38.1% over the past three months, and it holds a Zacks Rank of 2 (Buy) [5] - The Medical Info Systems industry, to which Clover Health belongs, has seen an average decline of 8.5% this year, indicating that both companies are performing well against their respective industry benchmarks [6]